Skip to Main Content

Paper Details

Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.
Blood
16
2023
AML, AML cells, CD4, CD4+ T-cell gene, CTLA-4, DNA methyltransferase, FOXP3, MDS, acute myelogenous leukemia, advanced myeloid disease, decitabine, experienced resident memory T cells, hematopoietic stem cell, ipilimumab, leukemia, leukemic, leukemic cells, leukemic progenitors, malignant clones, marrow-infiltrating cells, marrow-infiltrating regulatory T cells, myelodysplastic syndrome, patients, progenitor cell populations, transcriptomes
Author NameAffiliation
Len TaingDana-Farber Cancer Institute
Seunghee Kim-SchulzeHuman Immune Monitoring Center at the Icahn School of Medicine at Mount Sinai
Seunghee Kim-SchulzeHuman Immune Monitoring Center at the Icahn School of Medicine at Mount Sinai
Stacey GabrielBroad Institute of Massachusetts Institute of Technology and Harvard University
Stacey GabrielBroad Institute of Massachusetts Institute of Technology and Harvard University
Jerome RitzDana-Farber Cancer Institute
Jerome RitzHarvard Medical School
Jerome RitzBrigham and Women's Hospital
Donna NeubergDana-Farber Cancer Institute
Sacha GnjaticDana-Farber Cancer Institute
Sacha GnjaticDana-Farber Cancer Institute
Catherine J WuDana-Farber Cancer Institute
Catherine J WuBroad Institute of Massachusetts Institute of Technology and Harvard University
Catherine J WuHarvard Medical School
Catherine J WuBrigham and Women's Hospital
  • 1 - 15

Datasets

Release 1.2